

***THIS STUDY NO LONGER RECRUITING***

**Name of Study:** Study Of Fluoxetine In Autism (SOFIA)

**Location:** UNC's Neuroscience Hospital in Chapel Hill, NC

**Eligibility Criteria:** Children ages 5-17 diagnosed with Autistic Disorder

**Sponsors:** Autism Speaks and Neuropharm

**Contact Information:** Peter Robichaux, Study Coordinator, phone (800) 708-0048;  
email: [ASPIRE@unc.edu](mailto:ASPIRE@unc.edu)

Dear Parent,

Your child may be eligible to participate in a research study at UNC-Chapel Hill, under the guidance of the ASPIRE Research Team, that may help further the understanding of treatment options for children with autism.

In this study, we are trying to determine the effects of fluoxetine on repetitive behaviors associated with autism in children diagnosed with Autistic Disorder. The medicine is a quick-dissolving tablet that disappears in seconds once placed on the tongue. Fluoxetine has been FDA-approved for use in children (over the age of 7) for a different medical condition.

To minimize the occurrence of side effects, the medication will be given in slightly increasing doses until we determine a safe and effective dose for your child. Study visits are every two weeks for approximately 3 ½ months. Participants receive \$25 for each study visit, up to a total of \$225 for all 9 visits.

If you are interested in taking part, feel free to contact Peter Robichaux using the above information.

Sincerely,

Dr. Linmarie Sikich and the ASPIRE Research Team